2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M, Assouline S, Kim T, Kim W, Ozcan M, Hirata J, Penuel E, Paulson J, Cheng J, Ku G, Matasar M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal Of Clinical Oncology 2019, 38: 155-165. PMID: 31693429, PMCID: PMC7032881, DOI: 10.1200/jco.19.00172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalSurvival RateConceptsProgression-free survivalLarge B-cell lymphomaPolatuzumab vedotinB-cell lymphomaCR rateOverall survivalPola-BRR/R DLBCLRefractory diffuse large B-cell lymphomaIRC-assessed progression-free survivalDiffuse large B-cell lymphomaB-cell receptor componentsSingle-arm cohortsDuration of responseCohort of patientsCox regression methodRisk of deathMedian OSSafety profileKaplan-MeierTreatment optionsB cellsPolatuzumabBendamustineDLBCL
2018
Cancer subtype identification using somatic mutation data
Kuijjer M, Paulson J, Salzman P, Ding W, Quackenbush J. Cancer subtype identification using somatic mutation data. British Journal Of Cancer 2018, 118: 1492-1501. PMID: 29765148, PMCID: PMC5988673, DOI: 10.1038/s41416-018-0109-7.Peer-Reviewed Original ResearchConceptsSomatic mutation dataAssociated with mutationsNext-generation sequencing technologiesMutation dataBiological pathwaysSets of mutationsSignal transduction pathwaysCancer typesPan-cancer subtypesSequencing technologiesPhenotypic dataCancer Genome AtlasCancer subtype identificationTransduction pathwaysMutational driversSomatic mutationsSubgroup of patientsTargeted treatment optionsMutationsMutation patternsGenome AtlasClassification of patientsMutation profilesPrimary tumorPrognostic subtypes